Data protection essentials

Copyright © 2025 LexisNexis

Overview Content for select subtopic is not present

Powered by Lexis+®
Latest Life Sciences News

HaDEA launches €1m tender for European Health Data Space implementation support

The European Health and Digital Executive Agency (HaDEA) has launched a €1m EU4Health call for tenders on 1 August 2025 to provide administrative and secretarial support for the implementation of Regulation (EU) 2025/327 on the European Health Data Space (EHDS Regulation) and related digital health initiatives. The contract will support the coordination of governance bodies and expert groups central to the EHDS’s operational rollout. This initiative forms part of the 2025 EU4Health Annual Work Programme (action DI-p-25-66) and aims to strengthen health systems through effective digital governance.

MHRA issues policy of intent to create an Early Access service to innovative medical devices

The Medicines and Healthcare products Regulatory Agency (MHRA) has published a Statement of Policy Intent outlining plans to establish an Early Access service for innovative medical devices. The service will provide time-limited, conditional access to promising technologies ahead of full regulatory approval where clinical need and evidence of patient benefit exist. Initial focus will be on innovative diagnostic devices addressing urgent NHS needs. The Early Access service will build on experience from the Unmet Clinical Need Authorisation (UCNA) tool piloted in the Innovative Devices Access Pathway (IDAP). This forms part of MHRA's contribution to the UK Government's Life Sciences Sector Plan and 10-Year Health Plan.

HRA updates model commercial agreements for NHS and HSC research

The Health Research Authority (HRA) has announced, on the 30 July 205, updates to its suite of model commercial agreements used in clinical research with participating NHS and Health and Social Care (HSC) organisations. The revisions align the agreements with the model Commercial Chief Investigator Agreements (mCCIAs) published in June 2025 and incorporate feedback from users of earlier versions. The changes affect provisions on information sharing and contract signing, and the updated templates must be used in new IRAS submissions from 1 October 2025.

EMA guidance on masking personal data in Eudravigilance reports

The European Medicines Agency (EMA), in collaboration with the Heads of Medicines Agencies (HMA), has issued an addendum to its good pharmacovigilance practices (GVP) guidelines, specifically addressing the masking of personal data in individual case safety reports (ICSRs) submitted to EudraVigilance. This update follows an audit by the European Data Protection Supervisor, which highlighted the need for a unified masking policy across all entities reporting to EudraVigilance. The addendum outlines which data elements should be masked, left blank, or retained based on their relevance to pharmacovigilance processes such as signal management, duplicate detection and case processing.

View Life Sciences by content type :  
News
Practice notes
Precedents
Q&As

Popular documents

Priority between loss reliefs in loss making companies

Priority between loss reliefs in loss making companiesWhy does it matter?A company that is a member of a group and has incurred any of the types of losses available for surrender by way of group relief may, without any further rules, have more than one way in which to use the loss. There are a

Late payment penalties—inheritance tax

Late payment penalties—inheritance taxWhile interest often accrues on overdue tax, the late payment of certain taxes may also attract a penalty. For information on the interest accruing on overdue tax, see Practice Notes: IHT—payment deadlines on death—Interest on IHT and Interest on late paid

Contributory negligence in personal injury claims

Contributory negligence in personal injury claimsContributory negligence is a partial defence which can lead to a discount in damages.Other defences may also be relevant. See Practice Notes: Did the claimant consent to the risk of injury? and Was the claimant involved in an illegal activity?If a

Can shares in a limited company that have not been paid-up at all be cancelled?

Can shares in a limited company that have not been paid-up at all be cancelled?A limited company having a share capital may not alter that share capital, except in the ways listed in section 617 of the Companies Act 2006 (CA 2006). Shares in a company cannot simply be cancelled without following an
Priority between loss reliefs in loss making companies

Priority between loss reliefs in loss making companies

Priority between loss reliefs in loss making companiesWhy does it matter?A company that is a member of a group and has incurred any of the types of losses available for surrender by way of group relief may, without any further rules, have more than one way in which to use the loss. There are a

Late payment penalties—inheritance tax

Late payment penalties—inheritance tax

Late payment penalties—inheritance taxWhile interest often accrues on overdue tax, the late payment of certain taxes may also attract a penalty. For information on the interest accruing on overdue tax, see Practice Notes: IHT—payment deadlines on death—Interest on IHT and Interest on late paid

Contributory negligence in personal injury claims

Contributory negligence in personal injury claims

Contributory negligence in personal injury claimsContributory negligence is a partial defence which can lead to a discount in damages.Other defences may also be relevant. See Practice Notes: Did the claimant consent to the risk of injury? and Was the claimant involved in an illegal activity?If a

Can shares in a limited company that have not been paid-up at all be cancelled?

Can shares in a limited company that have not been paid-up at all be cancelled?

Can shares in a limited company that have not been paid-up at all be cancelled?A limited company having a share capital may not alter that share capital, except in the ways listed in section 617 of the Companies Act 2006 (CA 2006). Shares in a company cannot simply be cancelled without following an